SCHEMBL3971878

SCHEMBL3971878

Cc1cc(C)cc(CN2CCNCC2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 11/20 0.56
SIGMAR1 Q99720 1/20 0.55
MEN1 O00255 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
ADRA2C P18825 1/20 0.50
CCR2 P41597 1/20 0.50
CXCL12 P48061 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
LMNA P02545 1/20 0.47
GPR183 P32249 1/20 0.43
TACR1 P25103 1/20 0.41
CHRM3 P20309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22887326 0.89 CXCR4 (0.50) CXCR4SIGMAR1MEN1CHRM2CHRM1
SCHEMBL18754036 0.88 CXCR4 (0.53) CXCR4SIGMAR1MEN1CHRM2CHRM1
SCHEMBL17320452 0.84 CYP2D6 (0.59) CXCR4SIGMAR1MEN1KMT2ATACR1
SCHEMBL593734 0.82 SIGMAR1 (0.62) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL29756483 0.82 SIGMAR1 (0.62) CXCR4SIGMAR1MEN1KMT2AHRH3
SCHEMBL15872041 0.81 HRH3 (0.54) MEN1KMT2ATDP1HRH3
SCHEMBL13770498 0.80 CXCR4 (0.49) CXCR4SIGMAR1MEN1CHRM2CHRM1
Hydrochloric Acid SCHEMBL2923966 0.80 SIGMAR1 (0.61) CXCR4SIGMAR1MEN1KMT2ALMNA
SCHEMBL24627237 0.80 SIGMAR1 (0.55) CXCR4SIGMAR1MEN1CHRM2CHRM1
SCHEMBL245919 0.80 CXCR4 (0.81) CXCR4SIGMAR1MEN1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP disclosed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US disclosed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R CXCR4 190/4885SIGMAR1 480/4885MEN1 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.